Literature DB >> 24363104

The hypocretin system and psychiatric disorders.

Fabio Pizza1, Michele Magnani, Camilla Indrio, Giuseppe Plazzi.   

Abstract

The hypocretin system is constituted by a small group of hypothalamic neurons with widespread connections within the entire central nervous system producing two neuropeptides involved in several key physiological functions such as the regulation of sleep and wakefulness, motor control, autonomic functions, metabolism, feeding behavior, and reward. Narcolepsy with cataplexy is a neurological disorder regarded as a disease model for the selective hypocretin system damage, and also shares several psychopatological traits and comorbidities with psychiatric disorders. We reviewed the available literature on the involvement of the hypocretin system in psychiatric nosography. Different evidences such as cerebrospinal hypocretin-1 levels, genetic polymorphisms of the neuropeptides or their receptors, response to treatments, clinical, experimental and functional data directly or indirectly linked the hypocretin system to schizophrenia, mood, anxiety and eating disorders, as well as to addiction. Future genetic and pharmacological studies will disentangle the hypocretin system role in the field of psychiatry.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24363104     DOI: 10.1007/s11920-013-0433-9

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  102 in total

Review 1.  Hypothalamic regulation of sleep and circadian rhythms.

Authors:  Clifford B Saper; Thomas E Scammell; Jun Lu
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

2.  CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls.

Authors:  Frank Martin Schmidt; Elisabeth Arendt; Anne Steinmetzer; Matthias Bruegel; Jürgen Kratzsch; Maria Strauss; Petra Baum; Ulrich Hegerl; Peter Schönknecht
Journal:  Psychiatry Res       Date:  2011-07-14       Impact factor: 3.222

3.  Discrete cue-conditioned alcohol-seeking after protracted abstinence: pattern of neural activation and involvement of orexin₁ receptors.

Authors:  B Jupp; E Krstew; G Dezsi; A J Lawrence
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

4.  Treatment of acute mania with modafinil monotherapy.

Authors:  Peter Schoenknecht; Sebastian Olbrich; Christian Sander; Peter Spindler; Ulrich Hegerl
Journal:  Biol Psychiatry       Date:  2010-02-06       Impact factor: 13.382

Review 5.  Multiple roles for orexin/hypocretin in addiction.

Authors:  Stephen V Mahler; Rachel J Smith; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

6.  Low cerebrospinal fluid and plasma orexin-A (hypocretin-1) concentrations in combat-related posttraumatic stress disorder.

Authors:  Jeffrey R Strawn; Gail J Pyne-Geithman; Nosakhare N Ekhator; Paul S Horn; Thomas W Uhde; Lori A Shutter; Dewleen G Baker; Thomas D Geracioti
Journal:  Psychoneuroendocrinology       Date:  2010-02-08       Impact factor: 4.905

7.  Narcoleptic and schizophrenic hallucinations. Implications for differential diagnosis and pathophysiology.

Authors:  N Dahmen; M Kasten; K Mittag; M J Müller
Journal:  Eur J Health Econ       Date:  2002-11

Review 8.  Autonomic disturbances in narcolepsy.

Authors:  Giuseppe Plazzi; Keivan Kaveh Moghadam; Leonardo Serra Maggi; Vincenzo Donadio; Roberto Vetrugno; Rocco Liguori; Giovanna Zoccoli; Francesca Poli; Fabio Pizza; Uberto Pagotto; Raffaele Ferri
Journal:  Sleep Med Rev       Date:  2010-07-14       Impact factor: 11.609

Review 9.  Anxiety and arousal: physiological changes and their perception.

Authors:  R Hoehn-Saric; D R McLeod
Journal:  J Affect Disord       Date:  2000-12       Impact factor: 4.839

10.  Role of orexin in modulating arousal, feeding, and motivation.

Authors:  Natsuko Tsujino; Takeshi Sakurai
Journal:  Front Behav Neurosci       Date:  2013-04-18       Impact factor: 3.558

View more
  8 in total

1.  Psychosocial Profile and Quality of Life in Children With Type 1 Narcolepsy: A Case-Control Study.

Authors:  Francesca Letizia Rocca; Elena Finotti; Fabio Pizza; Francesca Ingravallo; Michela Gatta; Oliviero Bruni; Giuseppe Plazzi
Journal:  Sleep       Date:  2016-07-01       Impact factor: 5.849

2.  Orexinergic modulation of serotonin neurons in the dorsal raphe of a diurnal rodent, Arvicanthis niloticus.

Authors:  Widya Adidharma; Sean P Deats; Tomoko Ikeno; Jack W Lipton; Joseph S Lonstein; Lily Yan
Journal:  Horm Behav       Date:  2019-08-31       Impact factor: 3.587

Review 3.  Treatment Options for Narcolepsy.

Authors:  Lucie Barateau; Régis Lopez; Yves Dauvilliers
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

4.  Plasma Orexin-A Levels in Patients With Schizophrenia: A Systematic Review and Meta-Analysis.

Authors:  Shaoli Li; Ruili Zhang; Shaohua Hu; Jianbo Lai
Journal:  Front Psychiatry       Date:  2022-05-25       Impact factor: 5.435

Review 5.  Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy.

Authors:  Andrea Romigi; Giuseppe Vitrani; Temistocle Lo Giudice; Diego Centonze; Valentina Franco
Journal:  Drug Des Devel Ther       Date:  2018-08-30       Impact factor: 4.162

6.  Autism Spectrum Disorder and Narcolepsy: A Possible Connection That Deserves to Be Investigated.

Authors:  Annio Posar; Paola Visconti; Vincenza Blunda; Fabio Pizza; Giuseppe Plazzi
Journal:  Front Psychiatry       Date:  2020-04-08       Impact factor: 4.157

7.  Psychosis in patients with narcolepsy as an adverse effect of sodium oxybate.

Authors:  Tomi Sarkanen; Valter Niemelä; Anne-Marie Landtblom; Markku Partinen
Journal:  Front Neurol       Date:  2014-08-20       Impact factor: 4.003

8.  Comorbidity of Narcolepsy and Psychotic Disorders: A Nationwide Population-Based Study in Taiwan.

Authors:  Jia-Yin Yeh; Yu-Chiau Shyu; Sheng-Yu Lee; Shin-Sheng Yuan; Chun-Ju Yang; Kang-Chung Yang; Tung-Liang Lee; Chi-Chin Sun; Liang-Jen Wang
Journal:  Front Psychiatry       Date:  2020-03-25       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.